TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03933787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 5mg
Description: Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
Study: NCT05606185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retraction method
Description: Three dimensional evaluation of root resorption using cone beam computed tomography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retraction method
Description: Three dimensional evaluation of root resorption using cone beam computed tomography
Study: NCT02133625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Study: NCT03906656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Brace
Description: The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KAFO/SCO
Description: Current knee ankle foot orthosis that the subject was wearing at baseline
Study: NCT03776604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria were prophylactically administered the test drug PEG-rhG-CSF 48 h after chemotherapy.~Jin Youli（PEG-rhG-CSF）: The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were \<45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy.
Study: NCT01163981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of ultrasound guidance in cannulation
Description: Use of guidance with duplex ultrasound to complete cannulation of dialysis access
Study: NCT03324724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative cognitive-affective therapy for adolescents (ICAT-A)
Description: Participants will receive a 21-session individual psychotherapy approach with 4 phases. In addition, there will be 7-13 additional conjoint parent sessions.
Study: NCT04516629

Intervention type: DIAGNOSTIC_TEST
Intervention: heart rate variability, pulse diagnosis device
Description: check heart rate and pulse rate
Study: NCT01729481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m² iv weekly
Study: NCT03929471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Target weight correction protocol
Description: The intervention group will undergo target weight correction process based on time averaged fluid overload measurement (by bio-impedance).
Study: NCT01523392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Min - 90mg/Max - 180mg tablets (loading dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg (once daily)/Max - 600mg tablets (loading dose)
Study: NCT01729481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100mg, once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m², q2weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: 400 mg/m², q2weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m², q2weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
Study: NCT03933787

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ergometric test in healthy volunteers
Description: The volunteers will undergo an ergometric test in each session

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ergometric test in healthy volunteers
Description: The volunteers will undergo an ergometric test in each session
Study: NCT02638740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCALING AND ROOT PLANING (SRP)
Description: Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCALING AND ROOT PLANING (SRP)
Description: Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MUSTARD OIL AND SALT MASSAGE WITH SRP
Description: Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
Study: NCT02409251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and feedback
Study: NCT02617940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fissure sealant
Description: Surfaces allocated to this group will be treated with resin-based sealant (FluroShield®, Dentsply, United States of America) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. The sealant will be dispensed on the occlusal surface and light cured for 20 seconds (Optilight Max, Gnatus, Brazil).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral hygiene orientation
Description: Surfaces allocated to this group will be treated with sterile water application, as a placebo, without anesthesia and rubber dam. The active treatment in this group will be only oral hygiene orientations.
Study: NCT03067285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELV/COBI/FTC/TAF
Description: Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG/3TC/ABC + ELV/COBI/FTC/TAF
Description: Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
Study: NCT01036529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spinal Cord Stimulator
Description: Programming settings will be specific to the individual needs in accordance with the labeling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Back Surgery
Description: Different types of back surgery may be performed
Study: NCT03302455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eCBTI
Description: The brief eCBTI contains a one-week core course: sleep hygiene education, sleep restriction, stimulus control, relaxation audios, cognitive components, information about sleeping pills, and a brief overview. In addition, individual customized sleep restriction and stimulation control treatments were provided according to the subject's previous 2-week sleep status.
Study: NCT05782192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAL067
Description: SAL067 6mg(2 tablet) and placebo 25mg (1 tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin
Description: Alogliptin 25mg(1 tablet) and placebo 6mg (2 tablet)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 6mg (2 tablet) and placebo 25mg (1 tablet)
Study: NCT04581382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Exchange Plasma
Description: Undergo therapeutic plasma exchange

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT02614482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Administer medication to patients with overactive bladder
Study: NCT03696082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Activity
Description: Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
Study: NCT03910166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drug-coated balloon catheter（Orchid, Acotec）
Description: After predilation, using drug-coated balloon catheter to cover the whole treated segment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracranial artery stent system（APOLLO）
Description: stent assisted angioplasty
Study: NCT00755547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
Study: NCT02333981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: passive oral motor therapy for drooling
Description: 7 subjects aged 7-19 yrs were taken . All subjects received passive treatment which included light touch, stroking, vibration with (mechanical vibrator), tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
Study: NCT00469963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: quality-of-life assessment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 resin microspheres
Description: radiation therapy
Study: NCT02681120

Intervention type: PROCEDURE
Intervention: Biopsy

Intervention type: PROCEDURE
Intervention: Blood draw
Study: NCT02321891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroConn DC Stimulator Plus, tDCS
Description: transcranial electrical stimulation intervention with two experimental protocols

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroConn DC Stimulator Plus, tDCS
Description: transcranial electrical stimulation intervention with two experimental protocols
Study: NCT02189408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Study: NCT02159378

Intervention type: OTHER
Group type: OTHER
Intervention: Fructosamines

Intervention type: OTHER
Group type: OTHER
Intervention: Fructosamines
Study: NCT01193166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: 78, 117, 156, or 234 mg monthly injection for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: flexible dosing as prescribed by the study doctor for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: flexible dosing as prescribed by the study doctor for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: flexible dosing as prescribed by the study doctor for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidole
Description: flexible dosing as prescribed by the study doctor for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine
Description: flexible dosing as prescribed by the study doctor for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perphenazine
Description: flexible dosing as prescribed by the study doctor for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paliperidone
Description: flexible dosing as prescribed by the study doctor for 12 months
Study: NCT03785587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofpironium Bromide Gel, 15%
Description: Sofpironium Bromide Gel, 15%
Study: NCT01289106

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepavax-Gene
Description: 20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepavax-Gene
Description: 20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepavax-Gene
Description: 40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
Study: NCT01504581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM10660A
Description: Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HM10660A placebo
Description: Single dose of HM10660A Placebo

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: Single dose of Pegasys 180ug
Study: NCT03333395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized heparin and salbutamol
Description: HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized salbutamol
Description: S Group medications (control group) (30 patients) which was prepared by adding Salbutamol 5mg/2.5ml Nebulizer Solution + Na cl 0.9% 5ml.
Study: NCT01532544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilomedin and Integrilin
Description: Continuous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: low molecular weight heparin.
Study: NCT05189249

Intervention type: OTHER
Intervention: No intervention performed
Description: No intervention performed. Participants were enrolled retrospectively and medical records were accessed for data.

Intervention type: OTHER
Intervention: No intervention performed
Description: No intervention performed. Participants were enrolled retrospectively and medical records were accessed for data.
Study: NCT02907853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: as described above
Study: NCT01299571

Intervention type: DRUG
Intervention: Dutasteride
Description: Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study: NCT04147975

Intervention type: DIAGNOSTIC_TEST
Intervention: RaPID/BSI Test
Description: RaPID/BSI Test
Study: NCT01390324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of naratriptan+naproxen
Description: Tablets containing naratriptan 2,5 mg + naproxen 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naratriptan
Description: Tablets containing naratriptan 2,5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Tablets containing naproxen 500 mg
Study: NCT02681120

Intervention type: PROCEDURE
Intervention: Mammogram
Study: NCT04169776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve (taVNS) stimulation
Description: Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period. The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator. The device will be attached to the Cymba Concha of the ear via an electrode ear clip. The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment. TaVNS will be performed for 5 minutes daily for a period of 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve (taVNS) stimulation
Description: Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period. The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator. The device will be attached to the Cymba Concha of the ear via an electrode ear clip. The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment. TaVNS will be performed for 5 minutes daily for a period of 6 months.
Study: NCT04726657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed Human Isophane Insulin Suspension + Human Insulin Injection
Description: premixed human insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed Human Isophane Insulin Suspension + Human Insulin Injection
Description: premixed human insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed Insulin
Description: Premixed Insulin Analog Biphasic Aspart 30

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premixed Insulin
Description: Premixed Insulin Analog Biphasic Aspart 30
Study: NCT03236168

Intervention type: DRUG
Group type: OTHER
Intervention: Ivermectin
Description: A single weight based dose of ivermectin

Intervention type: DRUG
Group type: OTHER
Intervention: Permethrin 5%
Description: Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated

Intervention type: DRUG
Group type: OTHER
Intervention: Malathion Shampoo 0.5%
Description: Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
Study: NCT01522144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Decision support
Description: Using a clustered randomized method, computerized decision support, embedded in the electronic health record, was offered to selected primary care practices and outcomes of asthma care were compared to those practices without the computerized decision support.
Study: NCT01826266

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PER977, Placebo
Study: NCT00893100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: 2%,3 times daily